Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Howmet Aerospace Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.89 (market cap $8.04B), while Howmet Aerospace Inc trades at $276.96 (market cap $110.74B). The key difference: Howmet Aerospace Inc is far larger — about 13.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Howmet Aerospace Inc pays a 0.17% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | HWM | |
|---|---|---|
Market Cap | $8.04B | $110.74B |
Sector | Health | Industrials |
52-Week High | $339.75 | $283.23 |
52-Week Low | $241.71 | $171.00 |
Enterprise Value | $7.85B | $112.99B |
Dividend Yield | — | 0.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Howmet Aerospace (HWM) trades at $271.28, up 0.16% on the day, with a neutral technical signal but strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.22 exceeding expectations. Revenue growth and robust profit margins, including a 20.22% net income margin, support its premium valuation multiples. Recent news highlights strength in commercial aerospace demand as a key growth driver.
The outlook remains positive given analyst consensus with 84% buy ratings and a $317.63 price target, suggesting ~17% upside. However, elevated valuation ratios like a P/E of 64.22 pose risks if growth slows. Key catalysts include Q2 2026 results on August 6, 2026, while reliance on aerospace cycles and competitive pressures are monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
